News stories about Akari Therapeutics PLC (NASDAQ:AKTX) have been trending positive recently, AlphaOne Sentiment reports. AlphaOne, a service of Accern, identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akari Therapeutics PLC earned a news sentiment score of 0.44 on AlphaOne’s scale. AlphaOne also assigned media coverage about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have impacted AlphaOne Sentiment’s analysis:

Several analysts recently commented on AKTX shares. Zacks Investment Research raised Akari Therapeutics PLC from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a research note on Friday, March 24th. William Blair reaffirmed an “outperform” rating on shares of Akari Therapeutics PLC in a research note on Thursday, April 6th. Finally, Chardan Capital dropped their price objective on Akari Therapeutics PLC from $6.50 to $5.00 and set a “sell” rating on the stock in a research note on Monday.

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) opened at 16.37 on Friday. Akari Therapeutics PLC has a 52 week low of $6.22 and a 52 week high of $22.20. The company’s 50-day moving average price is $9.87 and its 200 day moving average price is $8.27. The firm’s market cap is $192.77 million.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Financial Market News and is the sole property of of Financial Market News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at

About Akari Therapeutics PLC

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

5 Day Chart for NASDAQ:AKTX

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with's FREE daily email newsletter.